Colchicine for the Treatment of Osteoarthritis of the Knee
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This prospective, double-blinded, placebo-controlled, randomized trial will enroll 120 SKOA
subjects at the NYU Center for Musculoskeletal Care. Patients meeting entry criteria will be
randomized 1:1 to treatment with colchicine or placebo daily for 3 months. Subjects will have
detailed evaluation of standardized clinical pain outcomes, candidate peripheral blood
biomarkers, baseline knee radiographs as well as MSK-US, and a subset will undergo evaluation
of their synovial fluid.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health